NCT04701918 2026-01-22
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Phase 2 Completed
Clinical Trials
17 trialsNCT03575013 2025-12-03
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
Phase 1 Completed
NCT05366725 2025-12-02
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT05431777 2025-04-01
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT03674424 2025-02-26
AURA
Jules Bordet Institute
Phase 2 Completed
NCT04822350 2025-01-27
AVENANCE
Pfizer
Completed
NCT03200587 2024-07-03
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Phase 1 Completed
NCT02603432 2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3 Completed
NCT03892642 2024-02-14
OU-SCC-ABC
University of Oklahoma
Phase 1/2 Completed
NCT05012865 2023-12-06
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
Completed
NCT03390595 2023-10-18
INDUCOMAIN
Associació per a la Recerca Oncologica, Spain
Phase 2 Completed
NCT04601402 2023-08-08
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
Phase 1 Completed
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT03179410 2021-03-05
PICK-NEPC
Duke University
Phase 2 Completed
NCT03403777 2019-03-05
Avelumab in Refractory Testicular Germ Cell Cancer.
National Cancer Institute, Slovakia
Phase 2 Completed